Janux Therapeutics, Inc. (JANX) is a Healthcare stock trading at $14.22 (as of 2026-06-18), with a market capitalization of $889.76M and a trailing P/E of -7.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Janux Therapeutics, Inc. is a biopharmaceutical company developing cancer therapies using its Tumor Activated T Cell Engager (TRACTr) platform. It is advancing TRACTr and related immunomodulator programs targeting antigens such as prostate-specific membrane antigen, EGFR, and trophoblast cell surface antigen 2, and a costimulatory bispecific program aimed at PD-L1 and CD28.